Croft, Julie (J);Farrow, Emily (E);Coxon-Meggy, Alexandra Harriet (AH);Gordon, Katie (K);Corrigan, Neil (N);Mather, Hannah (H);Stocken, Deborah D (DD);Dale, Megan (M);Chong, Huey Yi (HY);White, Judith (J);Knight, Laura (L);Meggy, Alun (A);Lloydwin, Christina (C);Tan, Betty (B);Douglas, Ashley (A);Powell, Ralph (R);Hepburn, Julie (J);Jayne, David (D);Torkington, Jared (J);Warwick, Andrea (A);Ng, Kheng-Seong (KS);Wilson, Kate (K);Knowles, Charles H (CH);Quyn, Aaron (A);Cornish, Julie (J);

Author information

BMJ Open.2025 Feb 03;15(2):e092612.doi:10.1136/bmjopen-2024-092612

Abstract

INTRODUCTION: As a result of improving survival rates, the adverse consequences of rectal cancer surgery are becoming increasingly recognised. Low anterior resection syndrome (LARS) is one such consequence and describes a constellation of bowel symptoms after rectal cancer surgery which includes urgency, faecal incontinence, stool clustering and incomplete evacuation. LARS has a significant adverse impact on quality of life (QoL) and symptoms are present in up to 75% of patients in the first year after surgery. Despite this, little is known about the natural history and there is poor evidence to support current treatment options.

METHODS AND ANALYSIS: The objectives of POLARiS are to explore the natural history of LARS and to evaluate the clinical and cost-effectiveness of transanal irrigation (TAI) or sacral neuromodulation (SNM) compared with optimised conservative management (OCM) for people with major LARS.POLARiS is a prospective, international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort design, with internal pilot phase, qualitative sub-study, process evaluation and economic evaluation. Approximately 1500 adult participants from UK hospitals and 500 from Australian hospitals who have undergone a high or low anterior resection for colorectal cancer in the last 10 years will be recruited into the cohort. Six-hundred participants from the UK and 200 participants from Australia, with major LARS symptoms, defined as a LARS score of ≥30, will be recruited to the randomised controlled trial (RCT) element. Participants entering the RCT will be randomised between OCM, TAI or SNM, all with equal allocation ratios.Cohort and RCT participants will be followed up for a 24-month period, completing a series of questionnaires measuring LARS symptoms and QoL, as well as clinical review for those in the RCT. A process evaluation, qualitative sub-study and economic evaluation will also be conducted.The primary outcome measure of the POLARiS cohort and RCT is the LARS score up to 24 months post-registration/randomisation. Analyses of the RCT will be conducted on an intention-to-treat basis. Comparative effectiveness analyses for each endpoint will consist of two pairwise treatment comparisons: TAI versus OCM and SNM versus OCM. Secondary outcomes include health-related QoL, adverse events, treatment compliance and cost-effectiveness (up to 24 months post-registration/randomisation).

ETHICS AND DISSEMINATION: Ethical approval has been granted by Wales REC 4 (reference: 23/WA/0171) in the UK and Sydney Local Health District HREC (reference: 2023/ETH00749) in Australia. The results of this trial will be disseminated to participants on request and published on completion of the trial in a peer-reviewed journal and at international conferences.

TRIAL REGISTRATION NUMBER: ISRCTN12834598; ACTRN12623001166662.